Compare HG & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HG | NKTR |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2023 | 1996 |
| Metric | HG | NKTR |
|---|---|---|
| Price | $34.74 | $69.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $32.00 | ★ $146.67 |
| AVG Volume (30 Days) | 291.5K | ★ 509.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | ★ 51.23 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $2,905,524,000.00 | $307,711,000.00 |
| Revenue This Year | $1.80 | N/A |
| Revenue Next Year | $12.52 | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | 24.70 | ★ 86.00 |
| 52 Week Low | $22.66 | $33.40 |
| 52 Week High | $37.31 | $109.00 |
| Indicator | HG | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 44.65 |
| Support Level | $33.49 | $70.24 |
| Resistance Level | $36.11 | $76.49 |
| Average True Range (ATR) | 0.68 | 2.88 |
| MACD | -0.10 | -0.31 |
| Stochastic Oscillator | 15.38 | 15.34 |
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select, and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.